A subset of flavaglines inhibits KRAS nanoclustering and activation
The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loa...
Saved in:
Main Authors: | Yurugi, Hajime, Zhuang, Yinyin, Siddiqui, Farid A., Liang, Hong, Rosigkeit, Sebastian, Zeng, Yongpeng, Abou-Hamdan, Hussein, Bockamp, Ernesto, Zhou, Yong, Abankwa, Daniel, Zhao, Wenting, Désaubry, Laurent, Rajalingam, Krishnaraj |
---|---|
Other Authors: | School of Chemical and Biomedical Engineering |
Format: | Article |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/149025 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CHARACTERIZTION OF LoxP-krasV12 TRANSGENIC ZEBRAFISH FOR INTESTINE SPECIFIC TUMORIGENESIS
by: ANEEKET JETLEY
Published: (2023) -
GENERATION AND ANALYSES OF krasV12 TRANSGENIC ZEBRAFISH TO STUDY INTESTINE TUMORIGENESIS
by: DIVYA RAGHURAM
Published: (2018) -
KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
by: Lam, KK, et al.
Published: (2024) -
RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
by: Omar, M.F.M., et al.
Published: (2014) -
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
by: Kim, H.R., et al.
Published: (2014)